Quick Answer
Barinthus Biotherapeutics plc. reported Net Income Loss of -$66.43 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -8.8% in Net Income Loss from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.82 million | Q2 2020: -$3.59 million | Q3 2020: $158.0 thousand | Q1 2021: -$15.27 million | Q2 2021: -$15.93 million | Q3 2021: -$4.56 million | Q1 2022: $2.60 million | Q2 2022: $15.69 million | Q3 2022: $8.24 million | Q1 2023: -$18.18 million | Q2 2023: -$23.80 million | Q3 2023: -$14.07 million | Q1 2024: -$15.49 million | Q2 2024: -$16.93 million | Q3 2024: -$8.11 million | Q1 2025: -$19.65 million | Q2 2025: -$21.12 million | Q3 2025: -$14.57 million.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Net Income Loss has declined by 275.2%.
- Historical annual values: Fiscal year 2025: -$66.43 million | Fiscal year 2024: -$61.07 million | Fiscal year 2023: -$73.35 million | Fiscal year 2022: $5.34 million | Fiscal year 2021: -$50.87 million | Fiscal year 2020: -$17.71 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: